Most Read Articles
5 days ago
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 11 Oct 2017

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 12 Oct 2017
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.

Circulating tumour necrosis factors predict CVD in chronic kidney disease

19 Jul 2017

Circulating tumour necrosis factors (cTNFR) 1 and 2 are independent predictors of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD), a new study reveals.

Over a median follow-up of 3.4±2.0 years, 3.7 percent (n=36) of CKD patients (n=984; mean age 49.7±15.8 years; 56.1 percent male) developed CVD. Significantly more patients in the highest tertile of cTNFR1 and cTNFR2 levels had CVD compared to the lowest tertile (p<0.001).

Multivariate regression analysis showed that cTFNR1 and cTNFR2 levels were significant independent predictors of CVD (hazard ratio [HR], 2.506; 95 percent CI, 1.186 to 5.295; p=0.016; and HR, 4.156; 1.913 to 9.030; p<0.001, respectively) and end-stage renal disease (ESRD; HR, 5.927; 3.412 to 10.296; p<0.001; and HR, 3.297; 2.192 to 4.959; p<0.001, respectively).

On the other hand, only cTNFR2 levels were associated with all-cause mortality (HR, 7.448; 2.319 to 23.925; p=0.001). Models were fully-adjusted for sex, age, inflammation and other CVD factors.

A total of 19 deaths (1.9 percent) and 174 ESRD cases (17.7 percent) were recorded over the follow-up period.

The most common comorbidity among the participants was hypertension (53.6 percent; n=527) followed by diabetes (27.1 percent; n=267). The mean estimated glomerular filtration rate (eGFR) and high-sensitivity C-reactive protein (hs-CRP) level were 50.8±31.6 mL/min/1.73 m2 and 0.7±2.4 mg/dL, respectively.

Eligible study participants were divided into tertiles according to measured cTNFR1 and cTNFR2 levels. The primary endpoint of the study was occurrence of nonfatal myocardial infarction, stroke, revascularization or cardiovascular death. Patients with histories of heart failure or organ transplants were excluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
5 days ago
Higher circulating levels of docosahexaenoic acid (DHA) and docosapentaenoic acid (DPA) appear to be protective against incident atherothrombotic and cardioembolic strokes, respectively, according to a recent study.
Roshini Claire Anthony, 11 Oct 2017

The prevalence of resistant hypertension may be lower than expected, particularly once pseudo-resistant hypertension due to treatment nonadherence is taken into account, according to a presentation at the recent APCH 2017.

Pank Jit Sin, 07 Jan 2015

Cardiovascular diseases (CVD) have been the main cause of death in the Malaysian population since 2007. This trend has continued, with the number of people dying from CVD-related causes increasing year on year. 

Tristan Manalac, 12 Oct 2017
Administration of a long-acting medication at the time that is most suitable for maximum patient compliance is the best approach in controlling blood pressure, said Dr. Trefor Morgan at the recently concluded 13th Asian-Pacific Congress of Hypertension (APCH 2017), held at the Suntec Singapore Convention and Exhibition Centre.